Anika Therapeutics Q2 revenue rises, lifts 2026 outlook
ANIK•Updated 2026 and 2027 outlook
- Anika raises 2026 total revenue growth outlook to 5%-10%, up from 1%-9%
- Company lifts 2026 adjusted EBITDA margin forecast to 13%-17%, from prior 5%-10%
- Anika cuts 2027 Commercial Channel revenue growth forecast to 5%-15%, from 10%-20%
Drivers of the quarterly results
- Commercial Channel growth - Record Commercial Channel revenue rose 17% yr/yr, driven by strong sales performance
- OEM Channel performance - OEM Channel benefited from strong transfer units, favorable order timing, and Monovisc volume growth
- Gross margin expansion - Higher sales volume, increased manufacturing production, and improved sales mix led to a 65% gross margin
Q2 revenue and profitability improve
- US osteoarthritis solutions maker's Q2 revenue rose 16% yr/yr on record commercial channel sales
- Adjusted EBITDA for Q2 reached $7.1 mln, highest since 2020, with gross margin expanding to 65%
- Company raised 2026 revenue and adjusted EBITDA margin guidance, citing improved operating leverage
Key financial details and analyst coverage
Related News
Nocera advances AI infrastructure strategy with agreement to acquire Qmax Technology, a Taiwan-based authorized distributor of Micron / Crucial memory and storage products
NCRA•
Genius Group receives initial ASX feedback on proposed dual listing, targets Q4 2026 debut
GNS•
